Kailera Therapeutics shares surged 62.5% in their Nasdaq debut on Friday after the company closed a $625 million initial public offering in the United States. The strong performance highlights the intense market interest in weight-loss treatments, a sector that is rapidly becoming one of the most lucrative in the pharmaceutical industry.
Waltham, Massachusetts-based Kailera Therapeutics sold approximately 39 million shares in an upsized offering priced at $16 per share, reaching the upper limit of its expected range. The stock opened for trading at $26, reflecting significant investor confidence as drugmakers compete for dominance in a market estimated to reach $150 billion annually by the end of the decade.












